CD22 CAR-T therapy also showed a promising treatment efficiency in r/r B-ALL patients including those relapsed after mCD19 CAR-T especially with CD19 negativity [20, 21]. This evidence concerns the gene CD22 and acute lymphoblastic leukemia.